Abstract
Actinomycin-D and vincristine are cytotoxic drugs commonly used to treat cancers in children. This prospective study assessed pharmacokinetic variability and toxicity of these drugs in children. Blood samples were collected in 158 patients. Actinomycin-D or vincristine concentrations were quantified using high-performance liquid chromatography–tandem mass spectrometry. Pharmacokinetic parameters were estimated using non-compartmental methods. Target toxicities were collected prospectively. Actinomycin-D pharmacokinetics (n = 52 patients) were highly variable. The median (coefficient of variation, CV%) area under the concentration–time curve (AUC) was 332 ng/mL·h. (110%); clearance was 4.6 L/h/m2 (90%); half-life was 25 h (60%). No patient met the defined criteria for myelosuppression. In multivariate analysis, none of the demographic nor pharmacokinetic parameters was predictors of acute hepatotoxicity. Vincristine pharmacokinetics (n = 132 patients) demonstrated substantial variability. The median (CV%) AUC was 78 ng/mL·h (98%); clearance was 17.2 L/h/m2 (67%); half-life was 14.6 h (73%). In multivariate analysis, the effect of increasing age for a given BSA was an increase in neuropathy while the effect of increasing BSA for a given age was a decrease in neuropathy. Conclusion: Pharmacokinetics of both drugs were highly variable. For actinomycin-D, there was no correlation between demographic or pharmacokinetic parameters and target toxicities. For vincristine, the correlations of age and BSA and neuropathy are confounded by the correlation between age and BSA in children and the ability to ascertain neuropathy in infants. Variability may be attributed to dose reductions and capped doses for both drugs. Investigation of BSA-based dosing in young children is warranted to decrease variability of exposure.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00280-021-04295-1/MediaObjects/280_2021_4295_Fig1_HTML.png)
References
Gupta AA, Anderson JR, Pappo AS et al (2012) Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children’s Oncology Group Soft Tissue Sarcoma Committee. Cancer 118:1130–1137
Paioli A, Luksch R, Fagioli F et al (2014) Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: influence of sex and age. J Chemother 26:49–56
van de Velde ME, Kaspers GL, Abbink FCH, Wilhelm AJ, Ket JCF, van den Berg MH (2017) Vincristine-induced peripheral neuropathy in children with cancer: a systematic review. Crit Rev Oncol Hematol 114:114–130
Langholz B, Skolnik JM, Barrett JS et al (2011) Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children’s Oncology Group. Pediatr Blood Cancer 57:252–257
Skolnik JM, Zhang AY, Barrett JS, Adamson PC (2010) Approaches to clear residual chemotherapeutics from indwelling catheters in children with cancer. Ther Drug Monit 32:741–748
Edwards AY, Skolnik JM, Dombrowsky E, Patel D, Barrett JS (2012) Modeling and simulation approaches to evaluate pharmacokinetic sampling contamination from central venous catheters in pediatric pharmacokinetic studies of actinomycin-D: a report from the Children’s Oncology Group. Cancer Chemother Pharmacol 70:83–94
Skolnik JM, Barrett JS, Shi H, Adamson PC (2006) A liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancer. Cancer Chemother Pharmacol 57:458–464
Mondick JT, Gibiansky L, Gastonguay MR et al (2008) Population pharmacokinetic investigation of actinomycin-D in children and young adults. J Clin Pharmacol 48:35–42
Hill CR, Cole M, Errington J, Malik G, Boddy AV, Veal GJ (2014) Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer. Clin Pharmacokinet 53:741–751
Crom WR, de Graaf SS, Synold T et al (1994) Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr 125:642–649
Kellie SJ, Koopmans P, Earl J et al (2004) Increasing the dosage of vincristine: a clinical and pharmacokinetic study of continuous-infusion vincristine in children with central nervous system tumors. Cancer 100:2637–2643
Plasschaert SL, Groninger E, Boezen M et al (2004) Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. Clin Pharmacol Ther 76:220–229
Moore AS, Norris R, Price G et al (2011) Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach. J Paediatr Child Health 47:875–882
Balis FM, Womer RB, Berg S et al (2017) Dosing anticancer drugs in infants: current approach and recommendations from the Children’s Oncology Group’s chemotherapy standardization task force. Pediatr Blood Cancer. https://doi.org/10.1002/pbc.26636
Funding
This work was supported by an NCTN Operations Center Grant (U10CA180866) and NCTN Statistics and Data Center Grant (U10CA180899) and the St Baldrick’s Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Skolnik, J., Hall, D., Barkauskas, D.A. et al. Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children’s Oncology Group Study ADVL06B1. Cancer Chemother Pharmacol 88, 359–365 (2021). https://doi.org/10.1007/s00280-021-04295-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-021-04295-1